Results from trials to determine the efficacy of antiinflammatory drugs such as the use of anti-TNFα in patients with psoriasis (Kannan et al., 2013) with antidepressant potential or the adjunctive use of cyclooxygenase-2 inhibitors for treating depression (Muller et al., 2010) have been encouraging. This evidence concerns the gene TNF and major depressive disorder.